Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 18 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have lost about 30.3% in that time frame, underperforming the S&P 500. Will the recent negative ...

12 analysts have shared their evaluations of Sarepta Therapeutics (NASDAQ:SRPT) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

Investors with significant funds have taken a bearish position in Sarepta Therapeutics (NASDAQ:SRPT), a development that retail traders should be aware of. This was brought to our attention today ...

Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:SRPT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

The projected annual revenue for Sarepta Therapeutics is 3,480MM ... of the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial data and insights ...

(RTTNews) - Sarepta Therapeutics (SRPT ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

Fintel reports that on March 31, 2025, RBC Capital downgraded their outlook for Sarepta Therapeutics (BMV:SRPT) from Outperform to Sector Perform. There are 956 funds or institutions reporting ...

Among these, Sarepta Therapeutics crashed following a report of a patient's death after treatment with Elevidys. Incyte also declined after study data disappointed investors. Shares of Sarepta ...